التفاصيل البيبلوغرافية
| العنوان: |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. |
| المؤلفون: |
Rini, Brian I.1 rinib2@ccf.org, Escudier, Bernard2, Tomczak, Piotr3, Kaprin, Andrey4, Szczylik, Cezary5, Hutson, Thomas E.6,7, Dror Michaelson, M.8, Gorbunova, Vera A.9,10, Gore, Martin E.11, Rusakov, Igor G.10, Negrier, Syivie12, Yen-Chuan Ou13, Castellano, Daniel14, Ho Yeong Lim15, Uemura, Hirotsugu16, Tarazi, Jamal, Celia, David17, Connie Chen18, Rosbrook, Brad16, Kim, Sinil19 |
| المصدر: |
Lancet. 12/3/2011, Vol. 378 Issue 9807, p1931-1939. 9p. |
| مصطلحات موضوعية: |
RANDOMIZED controlled trials, RENAL cell carcinoma, CLINICAL trials, CLINICAL drug trials, DRUG toxicity |
| مستخلص: |
The article presents a randomized phase three trial on the effectiveness of sorafenib and axitinib in patients with metastatic renal cell carcinoma (AXIS). The clinical test used sorafenib and axitinib, and participants were assessed by masked, analysed by intention of treating, and independent radiology review. The study treatment was stopped due to toxic effects in 14 patients or four percent patients treated with axitinib and 29 or eight percent patients treated with sorafenib. |
| قاعدة البيانات: |
Business Source Index |
